{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:21Z","timestamp":1792784961217,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NCI grants to SWOG supporting the research presented here are listed and apply to all co-authors."},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA244118"],"award-info":[{"award-number":["P01 CA244118"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA197633"],"award-info":[{"award-number":["R35 CA197633"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA244118"],"award-info":[{"award-number":["P01 CA244118"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"In addition to SWOG grants listed above."},{"name":"In addition to SWOG grants listed under the corresponding author that apply to all coauthors."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41591-020-1060-8","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T12:05:43Z","timestamp":1601899543000},"page":"1564-1568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-4659","authenticated-orcid":false,"given":"Alain P.","family":"Algazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6617-8421","authenticated-orcid":false,"given":"Adil I.","family":"Daud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Mehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thach-Giao","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Conry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary C.","family":"Doolittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph I.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Messino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Dennis F.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangaswamy","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Harker-Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Dreisbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth F.","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-8458","authenticated-orcid":false,"given":"Antoni","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Das Thakur","year":"2013","unstructured":"Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251\u2013255 (2013).","journal-title":"Nature"},{"key":"1060_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","volume":"27","author":"G Moriceau","year":"2015","unstructured":"Moriceau, G. et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27, 240\u2013256 (2015).","journal-title":"Cancer Cell"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto, P. A. et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 17, 1248\u20131260 (2016).","journal-title":"Lancet Oncol."},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444\u2013451 (2015).","journal-title":"Lancet"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer, R. et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 1315\u20131327 (2018).","journal-title":"Lancet Oncol."},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809\u2013819 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1060_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nm.4369","volume":"23","author":"Y Xue","year":"2017","unstructured":"Xue, Y. et al. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nat. Med. 23, 929\u2013937 (2017).","journal-title":"Nat. Med."},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.12.007","volume":"91","author":"S Valpione","year":"2018","unstructured":"Valpione, S. et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study. Eur. J. Cancer 91, 116\u2013124 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","volume":"18","author":"M Schreuer","year":"2017","unstructured":"Schreuer, M. et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF\nV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 18, 464\u2013472 (2017).","journal-title":"Lancet Oncol."},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.lungcan.2017.08.017","volume":"112","author":"HA Yu","year":"2017","unstructured":"Yu, H. A. et al. Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. Lung Cancer 112, 195\u2013199 (2017).","journal-title":"Lung Cancer"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.lungcan.2013.07.022","volume":"82","author":"S Minami","year":"2013","unstructured":"Minami, S. et al. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status. Lung Cancer 82, 271\u2013275 (2013).","journal-title":"Lung Cancer"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","volume":"18","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no, B. et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 18, 404\u2013412 (2017).","journal-title":"Lancet Oncol."},{"key":"1060_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.tranon.2019.10.003","volume":"13","author":"C Reger de Moura","year":"2020","unstructured":"Reger de Moura, C. et al. Intermittent versus continuous dosing of MAPK inhibitors in the treatment of BRAF-mutated melanoma. Transl. Oncol. 13, 275\u2013286 (2020).","journal-title":"Transl. Oncol."},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell 18, 683\u2013695 (2010).","journal-title":"Cancer Cell"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80\u201393 (2014).","journal-title":"Cancer Discov."},{"key":"1060_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00452-4","volume":"8","author":"R Somasundaram","year":"2017","unstructured":"Somasundaram, R. et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat. Commun. 8, 607 (2017).","journal-title":"Nat. Commun."},{"key":"1060_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387\u2013390 (2011).","journal-title":"Nature"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010).","journal-title":"Nature"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/bjc.2016.40","volume":"114","author":"SC Tate","year":"2016","unstructured":"Tate, S. C. et al. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours. Br. J. Cancer 114, 669\u2013679 (2016).","journal-title":"Br. J. Cancer"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-17-0401","volume":"7","author":"C Song","year":"2017","unstructured":"Song, C. et al. Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discov. 7, 1248\u20131265 (2017).","journal-title":"Cancer Discov."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1060-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T20:49:30Z","timestamp":1633380570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1060-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-1060-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"7 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.P.A.\u2014research support, advisory board member, consultant, shareholder and honorarium recipient, OncoSec. Advisory board member and stock shareholder for Valitor Biosciences. Advisory board member and honorarium recipient for Regeneron and Array. Research support from Acerta, Amgen, AstraZeneca, BMS, Dynavax, Genentech, Idera, Incyte, ISA, LOXO, Merck, Novartis, Sensei and Tessa. M.O.\u2014consultant for Merck, Daiichi Sanko and Glycomimetics. DSMC member for Celgene and Glycomimetics. A.I.D.\u2014research funding from GSK, Novartis, Merck, BMS, Incyte and Checkmate. Consultant for Pfizer, Roche, Incyte, BioNTech, Merck and BMS. J.M.M.\u2014consultant and honorarium recipient for Array. Grant support\/contractor for Merck. Research support from Sanofi, Polynoma, Amgen, AstraZeneca, Incyte, Macro Genics and BMS. Research support and advisory board member for EMD Serono. K.K.\u2014research support from Merck, BMS, Immunocore, Medpace and Novartis. G.C.D.\u2014speakers bureau for Novartis, BMS and Merck. J.I.C.\u2014speakers bureau for BMS and Merck. Research support to institution BMS, Aveo, Argos Therapeutics, Genentech\/Roche and Nektar. Immediate family member is employed full time by BMS. K.F.G.\u2014consulting for BMS, Genentech, Castle Biosciences, Novartis, Array and Pfizer. R.S.L.\u2014research support from Array, Merck, Novartis, OncoSec and BMS. Honorarium recipient from Amgen. A.R.\u2014consultant\/independent contractor and honorarium recipient: Amgen, Chugai, Merck, Novartis and Sanofi. Advisor\/board member and honorarium recipient: Arcus, Bioncotech, Compugen, CytomX, ImaginAb, Isoplexis, Merus, Rgenix, Lutris, PACT Pharma and Tango Therapeutics. Stock shareholder (self-managed): Arcus, Compugen, CytomX and Merus. Research support from Agilent and BMS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}